Exelixis | Beneficio Operativo



Operating Profit Cambio Fecha
Acadia Pharmaceuticals USD 153.5M 121.86M 2024-12
Agios Pharmaceuticals USD -125037000 1.11B 2024-12
Amgen USD 2.31B 182M 2024-12
AstraZeneca USD 3.67B 1.64B 2025-03
Bayer EUR 3.53B 7.35B 2024-12
BioMarin Pharmaceutical USD 161.41M 47.51M 2024-12
Bristol-Myers Squibb USD 3.41B 2.62B 2025-03
Cytokinetics USD -139040000 1.76M 2024-12
Eisai JPY 27.56B 13.14B 2024-12
Eli Lilly USD 5.41B 259.6M 2025-03
Exelixis USD 163.21M 27.13M 2025-01
Genmab DKK 2.19B 89M 2024-12
Glaxosmithkline GBP 702M 513M 2024-12
Incyte USD 205.17M 96.34M 2025-03
Ionis Pharmaceuticals USD -146000000 35.18M 2025-03
MacroGenics USD -16587000 70.78M 2024-12
Merck USD 5.87B 1.57B 2025-03
Moderna USD -1050000000 196M 2025-03
Neurocrine Biosciences USD 142M 41.8M 2024-12
Novartis USD 2.28B 1.34B 2024-12
Pfizer USD 3.67B 4.08B 2025-03
Sanofi EUR 861M 2.77B 2024-12
Takeda JPY 66.94B 117.3B 2024-12
Ultragenyx Pharmaceutical USD -122278000 9.71M 2024-12
Xencor USD 4.05M 66.33M 2024-12



Exelixis Beneficio Operativo - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.